Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi NextCODE, a Genomics CRO, Closes $240 Million Series B Round

publication date: Sep 7, 2017

WuXi NextCODE completed a Series B fundraising with $240 million in new capital for its genomics CRO operations. In May, the company closed the first tranche of the round. NextCODE is WuXi AppTec's platform for genomic data, and Dr. Ge Li, Chairman of the company, said NextCODE is working towards sequencing millions of genomes. Two years ago, WuXi AppTec paid $65 million to acquire NextCODE, which had developed a genomics platform based on the largely homogeneous genomic profile of Iceland. Sequoia China led the B round. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital